Evidence map›Paper›PMID 30535427›Full record

ArticleInternational journal of molecular medicine2019

Atorvastatin downregulates HSP22 expression in an atherosclerotic model in vitro and in vivo.

Qi Chen, Jian Xiang, Ren Gong, Hai-Yang Fang, Cong-Cong Xu, Hong-Zhou Zhang, Yan-Qing Wu

Open access · hybridAbstract read
In one paragraph

Article in International journal of molecular medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Qi ChenDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Jian XiangDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Ren GongDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Hai-Yang FangDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Cong-Cong XuDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Hong-Zhou ZhangDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Yan-Qing WuDepartment of Cardiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China.
Second Affiliated Hospital of Nanchang University · CNNanchang University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the pathological functions of heat shock protein 22 (HSP22) is the association with inflammatory diseases and atherosclerosis. However, the effects of a high‑fat diet (HFD) or oxidized low‑density lipoprotein (ox‑LDL) combined with atorvastatin (ATV) on HSP22 expression are entirely unknown. The present study investigated the effects of ATV on HSP22 expression in HFD‑induced atherosclerotic apolipoprotein E‑deficient (ApoE‑/‑) mice and in ox‑LDL‑induced human umbilical vein endothelial cells (HUVECs). Furthermore, the influence of HSP22‑knockdown on the HFD- or ox‑LDL‑induced atherosclerotic model was also examined. It was found that HFD or ox‑LDL treatment significantly increased HSP22 expression in the serum and aorta, accompanied by decreased phosphorylated (p)‑endothelial nitric oxide synthase (p-eNOS) activity and activated p38 mitogen‑activated protein kinase (MAPK). However, these effects were suppressed by treatment with ATV. Furthermore, HSP22-knockdown showed reduced ox‑LDL‑induced lesions, evidenced by increased p‑eNOS activity and inactivated p38 MAPK, while suppression of cell proliferation inhibition and cell cycle arrest were also observed. Taken together, the results of this study suggest that HFD or ox‑LDL increased the expression of HSP22 and p‑p38 MAPK, and decreased the p‑eNOS activity in vitro and in vivo, and ATV could reduce the effects by downregulating HSP22 expression.

Indexed as

AnimalsAnticholesteremic AgentsAtherosclerosisAtorvastatinCell Cycle CheckpointsDiet, High-FatDown-RegulationHeat-Shock ProteinsHSP20 Heat-Shock ProteinsHumansHuman Umbilical Vein Endothelial CellsLipoproteins, LDLMaleMiceMolecular ChaperonesMuscle ProteinsAnticholesteremic AgentsAtorvastatinHeat-Shock ProteinsHSP20 Heat-Shock ProteinsHSPB8 protein, humanHspb8 protein, mouseLipoproteins, LDLMolecular ChaperonesMuscle ProteinsNitric Oxide Synthase Type IIINOS3 protein, humanNos3 protein, mouseoxidized low density lipoproteinp38 Mitogen-Activated Protein KinasesProtein Serine-Threonine Kinases

Identifiers

PMID30535427
PMCPMC6317682
OpenAlexW2903137649

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.